The U.S. Food and Drug Administration (FDA) has asked for modifications to the risk evaluation and mitigation strategy — known…
Articles by Margarida Maia, PhD
Neuromyelitis optica spectrum disorder (NMOSD) is associated with a faster loss of white matter volume in the brain, but…
Nearly two in 10 neuromyelitis optica spectrum disorder (NMOSD) patients develop new asymptomatic brain and spinal cord lesions during…
Neuromyelitis optica spectrum disorder (NMOSD) patients have significantly poorer nutritional status than healthy people which is associated with worse…
The presence of certain self-reactive antibodies called antinuclear antibodies (ANAs) in the blood is associated with worse disability and more…
Long-term use of the approved therapy Soliris (eculizumab) safely and effectively prevents relapses in the real world in people…
The presence of lesions in the brain’s middle medulla, a control center for breathing, increases the likelihood of acute respiratory…
Having optic neuritis — inflammation of the nerves that relay information between the eyes and the brain — as a…
Achieving nine goals could help address inequities with access to properly diagnosing and treating neuromyelitis optica spectrum disorder (NMOSD),…
Uplizna (inebilizumab) reduces the number and size of subclinical lesions — those that cause no apparent symptoms — in…